Biomarker to Predict Resistance to Doxorubicin Cancer Therapy
Background:
The Laboratory of Human
Carcinogenesis, Center for Cancer Research, National Cancer
Institute, National Institutes of Health, is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize a manganese
superoxide dismutase (MnSOD) genotyping assay to assess a patient's
response to doxorubicin combination therapy.
Technology:
Major drawbacks of current cancer
therapies are the individual differences in both the response and
the cytotoxic side-effects that are associated with them. This
research identified a MnSOD polymorphism as a novel biomarker for
the prognosis of doxorubicin therapeutic response in breast cancer
patients. This technology can be developed into an assay to screen
patients for their response to doxorubicin treatment. Further, as
the MnSOD variant allele is common in the population (about 20% of
patients have the homozygous variant genotype), it is a common risk
factor and biomarker that predicts poor response to doxorubicin
therapy in breast cancer, and likely in other types of cancer.
This technology is also available for licensing under an exclusive
or non-exclusive patent license. Please contact Jennifer Wong,
Ph.D. of the NIH Office of Technology Transfer at 301-451-7337 or
wongje@mail.nih.gov.
Potential Application
Areas:
- A novel genetic marker to predict breast cancer patient
survival with doxorubicin treatment.
- A screening test that allows for individualized treatment
according to patient MnSOD genotype.
Further R&D
Required:
- Future studies include determining the mechanism in which the
polymorphism modulates doxorubicin toxicity.
- Validation in independent studies
Current State of
Development:
MnSOD genotyping assay is available. The assay is accurate and
reliable.
IP Status:
U.S. Provisional Application filed May, 2006
Contact
Information:
John D. Hewes, Ph.D., NCI
Technology Transfer Center
Phone: 301-435-3121
E-mail: Hewesj@mail.nih.gov
Reference: #453 BW
Updated 10/24/2007
This opportunity is also listed under the following categories: